Recent Updates
Recently added Catalysts
EDIT

Editas Medicine to Present at Investor Conferences in May

Key Takeaway: CAMBRIDGE, Mass., May 08, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor conferences in May. Details are as follows: Bank of America Merrill Lynch 2017 Heal

Conference Participation Details

UBS Global Healthcare Conference
Date: November 11, 2025
Time: 8:45 a.m. ET
Format: Fireside Chat

How to Access

Investors and the general public can listen to both sessions live at:

https://investor.viatris.com

Archived versions will be available following the live events for a limited time.

Full Press Release Details

CAMBRIDGE, Mass., May 08, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor conferences in May. Details are as follows:
Bank of America Merrill Lynch 2017 Health Care Conference
Date: Wednesday, May 17, 2017
Forum: Panel Discussion on Gene Therapy and Gene Editing
Time: 4:40 p.m. ET
Location: Las Vegas
UBS Global Healthcare Conference
Date: Monday, May 22, 2017
Forum: Company Presentation and Breakout Session
Time: 8:00 a.m. ET
Location: New York
A live webcast of the presentation will be available on the Investors & Media section of the Editas website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the presentation.
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.

Tags

Last updated: May 8, 2017